Been on the reta waiting list for months - anyone heard anything?

Dr.RaviCardio said:

The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either.

I would rather people stopped quoting the 24% as if it were a licensed outcome. It is a phase 2 result in a few hundred participants with no cardiovascular endpoint and no long-term safety data, and this board has a habit of treating pipeline numbers as settled.

Ask again with the specifics and you will get a better answer than this one.

The figures, for anyone assembling their own picture. The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the same conditions. Nobody wants that answer and it is still the answer.

mike.trainer_LA said:

I would rather people stopped quoting the 24% as if it were a licensed outcome.

Adding the part of the answer the thread has not reached. The distinction that resolves most of these threads is between what is true on average and what is true for one person. Both are real; they answer different questions and get quoted as if they were the same one.

I would rather be corrected than agreed with, if it comes to it.

One thing that is still open after denise_HTX’s answer:

What the phase 2 dropout pattern implies about how the phase 3 tolerability will read?

Reporting back.

Rereading it with the dropout table open changed my view. I still think it is the most interesting molecule in the pipeline; I no longer think the 24% is the number that will end up on a label.